
Test Template Ronny Allan
Discover more from Ronny Allan – Living with Neuroendocrine Cancer Subscribe to get the latest posts sent to your email. Type your email… Subscribe
I was diagnosed in 2010 with metastatic NETs clearly showing on CT scan, the staging was confirmed via an Octreotide Scan which in addition pointed out two further deposits above the diaphragm (one of which has since been dealt with). In addition to routine surveillance via CT scan, I had two further Octreotide Scans in 2011 and 2013 following 3 surgeries, these confirmed the surveillance CT findings of the remnant disease. The third scan in 2013 highlighted an additional lesion in my thyroid (still under a watch and wait regime, biopsy inconclusive – but read on….).
In 2018, my 6 monthly CT scans seem to have been adequate surveillance cover and all my tumour and hormone markers remain normal. I was reasonably fit and well for a (then) 62-year-old.
At a 6 monthly surveillance meeting in May 2018, I was offered my very first Ga68 PET/CT. I was initially excited but also later I felt apprehensive. Let me explain below why I had a mix of emotions. I will now adopt the term “SSTR PET” (somatostatin receptor PET) to cover all versions (e.g. Ga68, Cu64).
Of course, these feelings will be felt in those diagnosed before SSTR PET were brought into routine use. Where there has been little access to SSTR PET, this may also apply to those getting or just had their first SSTR PET. For people diagnosed and have only been scanned by SSTR PET, then some of these feelings may still apply.

I wrote a comprehensive post about the Ga68 PET entitled “…. Into the unknown” – so named because that is how I felt at the time. I have now renamed that blog “All you need to know about SSTR PET“.
It’s well-known that the Ga68 is a far superior nuclear scan to the elderly Octreotide type, showing much greater detail with the advantage of providing better predictions of PRRT success if required downstream. It has been a game-changer for many and if you look below and inside my article, you will see statistics indicating just how it can ‘change the game’ in somatostatin receptor-positive Neuroendocrine Cancer diagnostics and treatment.
I was going to get the latest ‘tech’ and thought it could be useful confirmation of what I already knew. I also felt lucky to get one, they are limited in UK and there has to be a clinical need to get access. I was excited because it might just rubber-stamp the stability I’ve enjoyed for the 5 or so years since my last surgery in 2012.
I also felt apprehensive because of the ‘unknown’ factor with cancer, i.e. what is there lurking in my body that no one knows about, and which might never harm me, but this scan will light it up demanding attention. I wrote about the phenomenon of physiologic uptake where these types of nuclear scans can show up things that are not NET, or not even cancer. I started to hope doctors were experienced enough to work out what is important, what isn’t and what just needs to be noted. I covered some of these concerns in my post “How to interpret your SSTR PET scan results“.
I was also apprehensive in case this more detailed scan found something potentially dangerous. As we know, NETs are mostly slow-growing but always sneaky. Of course, any new tumours found may not actually be new, they were just not seen until the Ga68 PET was able to uncover them, or not big enough to be seen on the last scan.
To confirm the advantages of SSTR PET over Octreotide scans, a study comprising 1,561 patients reported a change in tumour management occurred in over a third of patients after SSTR PET/CT even when performed after an Octreotide scan.
In an older study, this slide from a NET Research Foundation conference shows some more interesting statistics:

Not sure I can class it as that. I’m now in the ‘bone met club’ and although that single metastasis has probably been there for some time, it’s not a ‘label‘ I was keen to add to my portfolio. The scan has brought more light to my thyroid issue. In fact, it indicates even more potential issues above the diaphragm including what looks like a new sighting around my left pectoral lymph nodes. The scan also lights up a known and potential issue in the left clavicle lymph nodes first pointed out via Octreotide scan in 2010 and biopsy negative. Two subsequent CT scans since this Ga68 PET would indicate the lymph node uptakes of the supraclavicular and sub-pectoral nodes are not reflected in a pathologically enlarged problem, indicating these are physiological or ‘reactive’ in nature.
In addition to a nuclear scan update (routine surveillance), it also formed part of an investigation into the progression of my retroperitoneal fibrosis (initially diagnosed 2010 but potential growth spotted on recent surveillance CT). The Ga68 PET doesn’t make fibrosis light up (it’s not cancerous) but there are some hotspots in the area of the aorta close to the fibrosis, a potential source of the cause. Surgery is on hold for now as my kidney function is fine following a renal MAG3 scan which reported no blockages.
Bone Metastases. The report indicates “intense focal uptake” on my 11th right rib. It always amazes me that people can be thankful for having an extra tumour. I’m thankful I only have a single bone metastasis. I had read so many stories of those who got their first Ga68 PET and came back with multiple bone metastases. I’ll accept one and add to my NET CV. I have no symptoms of this bone metastasis and it will now be monitored going forward. I’m annoyed that I don’t know how long it’s been there though!
Confirmation and a better understanding of the following:
That the above findings are pretty much the same and everything looks stable. I appear to have a dominant retrocaval node which is unchanged in size since 2018 and the SUV is less than it was in 2018 (22). It’s now coming out as 19.5. I realise SUVs are not an exact science (read more about SUV here). This is a strange area for lymph node spread in a NET and when I search, it’s all related to genito-urinary cancers such as ovarian and testicular.
Note: The radiologist noted I had some right-side axillary node reaction (armpit) which will have been due to a recent COVID vaccination. I had my 2nd vaccine at the end of March and on the right arm. Read about this phenomena by clicking here.
As this partly triggered the Ga68 PET, I’ve learned so much about desmoplasia since this issue arose and I now fully understand why I had to have radical surgery back in 2010 to try to remove as much of the fibrosis as possible from the aortic area. You can read more about this in my article. Desmoplasia via fibrosis is still very much of an unknown and mystery condition in NETs. I now know that my fibrosis is classed as clinically significant and according to the Uppsala study of over 800 patients inside my article, I’m in 5% of those affected in this way (2% if you calculate it using just the retroperitoneal area).
It appears this problem may have come back with new fibrosis or growth of existing fibrosis threatening to impinge on blood vessels related to the kidneys and also my ureters (kidney to bladder urine flow). The Ga68 PET doesn’t make fibrosis light up but there are some hotspots in the area of the aorta close to the fibrosis. This is being closely monitored.
I didn’t expect this particular problem to return – it was a bit of a shock. My hormone markers have been normal since 2011 and this just emphasises the importance of scans in surveillance.
There’s still quite a lot of hype surrounding the Ga68 PET scan and I get this. However, it does not replace conventional imaging (CI) such as CT and MRI scans which still have their place in routine surveillance and also in diagnostics where they are normally at least the trigger for ‘something is wrong’. For the vast majority, a CT/MRI scan will find tumours and be able to measure reductions and progress in regular surveillance regimes. In fact, the retroperitoneal fibrosis has appeared on every CT scan since diagnosis, but the changes were highlighted on my most recent standalone CT and it triggered the Ga68 PET (although my new Oncologist did say I was due a revised nuclear scan). It’s not a ‘functional’ issue (although it is caused by functional tumours). In fact, the fibrosis is not mentioned on the Ga68 PET because it is not lighting up – but the lymph nodes surrounding it are mentioned and they are under suspicion of being active.
There are actually recommended usages for the Ga68 PET scan and other SSTR PETs here.
Read a summary of all conventional scans and nuclear scans by clicking here. In my own experience it can be a case of now you see them, now you don’t, and radiologists and specialists experienced in how best to use and interpret every type of scan to get the best views of NETs is a really important factor. And I cannot emphasise enough that interpreting scans for NETs is a bit of a dark art.
My game has changed a bit. However, at least my medical team and I now know what WE are dealing with, and the risks vs benefits of intervention are under review. I’m heavily involved in that.
All of the above most likely applies to any other variant of somatostatin receptor (SSTR) PETs being deployed. The other approved radioligand used in SSTR PET for Neuroendocrine Cancer is the 64Cu DOTATATE which is said to pick more lesions (perhaps including some that were always there but not visible on Ga68). Read about the “copper scan” here.

Thanks for reading.
Blog Facebook. Like this page please.
Personal Facebook. Like this page please.
Awareness Facebook Like this page please.
Follow me on X (formerly twitter)
Check out my online presentations
Check out my WEGO Health Awards


Discover more from Ronny Allan – Living with Neuroendocrine Cancer Subscribe to get the latest posts sent to your email. Type your email… Subscribe

Bone metastases in Neuroendocrine Tumours (NET) Many of you will know that I am a stage IV small intestine NET and I have one bone

What is Radioligand Therapy? When you browse the internet, you may see the term “Radioligand Therapy (RLT)” and wondered what it was. There’s a simple

D Day I was 54 years and 9 months old at diagnosis on 26th July 2010. For the first few months, I had no idea

USA – Prevalence of Neuroendocrine Neoplasms (NENs) breaches the Orphan Disease threshold for the first time (officially) The latest US SEER figures confirm that staggering

Reframing Neuroendocrine Neoplasms: Beyond “Rare” Neuroendocrine neoplasms (NENs) have outgrown the “rare disease” label. e.g. Across the U.S., UK, and Australia, they now rank among

Sincer 2015, my message has not changed. My message continues to be justified because since then, many important voices in the NEN community have repeated

Here is the monthly summary of September and October 2025 on RonnyAllan.NET – Every share helps someone understand or even work towards a diagnosis,

Scroll down to check out the doctors list just below Scroll down to also see information on “NET Aware” Dietitians. Important note The accuracy of
I would also mention those who contributed to my “Tea Fund” which resides on PayPal. You don’t need a PayPal account as you can select a card but don’t forget to select the number of units first (i.e. 1 = £4, 2 = £8, 3 = £12, and so on), plus further on, tick a button to NOT create a PayPal account if you don’t need one. Clearly, if you have a PayPal account, the process is much simpler
Through your generosity, I am able to keep my sites running and provide various services for you. I have some ideas for 2023 but they are not detailed enough to make announcements yet.
This screenshot is from every single post on my website and depending on which machine you are using, it will either be top right of the post or at the bottom (my posts are often long, so scroll down!)
Subscribe to get the latest posts sent to your email.
Subscribe now to keep reading and get access to the full archive.